mubritinib,
TAK-165,
Mubritinib,
366017-09-6,
TAK 165,
Mubritinib (TAK 165),
TAK-165,
TAK165,
UNII-V734AZP9BR,
V734AZP9BR,
4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole,
C25H23F3N4O2,
(E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole,
1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole,
1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-1,2,3-triazole,
Mubritinib (USAN/INN),
Mubritinib [USAN:INN],
(E)-4-[[4-[4-(1H-1,2,3-Triazol-1-yl)butyl]phenoxy]methyl]-2-[4-(trifluoromethyl)styryl]oxazole,
1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole,
1-[4-[4-[[2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole,
Mubritinib-TAK-165,
Mubritinib; TAK-165,
Mubritinib - TAK 165,
SCHEMBL94943,
MLS006010161,
AC1O61A3,
GTPL6011,
CHEMBL1614707,
Mubritinib, >=98% (HPLC),
AOB6507,
SYN1112,
ZTFBIUXIQYRUNT-MDWZMJQESA-N,
HMS3678A21,
BCP02837,
EX-A2107,
ABP001021,
BS0278,
MFCD09954135,
s2216,
ZINC11679877,
AKOS015918001,
AC-5248,
BCP9000012,
CS-3954,
DB12682,
SB19375,
NCGC00346582-08,
AN-11205,
AS-16256,
BC656820,
HY-13501,
SC-23332,
SMR004458708,
AB0033770,
RT-015873,
M3058,
SW219659-1,
X7505,
D04025,
Z-3270,
017M096,
A823310,
I14-8814,
TAK 165 , TAK165 , TAK-165 , 366017-09-6,
(E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenyl1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole,
(E)-4-[[4-[4-(1H-1,2,3-Triazol-1-yl)butyl]phenoxy]methyl]-2-[4-(trifluoromethyl)styryl]oxazole / TAK 165,
[4-[4-[[2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole,
1-(4-(4-((2-((E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)oxazol-4-yl)methoxy)phenyl)butyl)-1H-1,2,3-triazole,
1-(4-{4-[(2-{2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1,2,3-triazole,
1-[4-[4-[[2-[(E)-2-(4-trifluoromethylphenyl)ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]-butyl]-1H-1,2,3-triazole,
1-[4-[4-[[2-[(E)-2-(4-trifluoromethylphenyl)ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole,
1-[4-[4-[[2-[(E)-2-[-4-(trifiuoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole,
1-[4-[4-[[2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]triazole,
1H-1,2,3-triazole, 1-(4-(4-((2-((1E)-2-(4-(trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-,
4-[[4-[4-(1,2,3-triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole,
4-[[4-[4-(1-triazolyl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]oxazole,
4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]vinyl]oxazole,
Mubritinib [USAN],
D0A9OV,
cc-594,
ACN-040203,
C25-H23-F3-N4-O2,
CID6444692,
MK-0752,
A10612,